The committee issued new recommendations related to 300 mg ibuprofen, gabapentin and pregabalin, cyclobenzaprine, and tizanidine.
The committee issued new recommendations related to 300 mg ibuprofen, gabapentin and pregabalin, cyclobenzaprine, and tizanidine.
Matters discussed included physician dispensing, missed appointment fees, passive therapy utilization, and interpreter bill denials.
The April 15th hybrid meeting will take place from 12:30 PM to 2:30 PM PST, covering a wide variety of pharmacy topics.
The state’s definition of “compounded prescription drug” would be updated to fall in line with federal standards.
One bill proposes the use of the ODG guidelines, while another bill would establish a fee schedule similar to neighboring states.
While the report addresses multiple topics, a significant focus was given to the expanding role of pharmacists as a healthcare provider.
Originally meant to address compound medications, the bill has been expanded to create limitations for physician dispensing.
The meeting covered potential updates to treatment guidelines, specifically for physical therapy, as well as other topics.
The bill would allow payers to direct prescriptions to pharmacy networks and create limits for physician dispensing and compounds.
New bills would address compounds, deadlines for authorization decisions, and more.
The meeting discussed proton pump inhibitors and the need to review utilization, and future meetings will address GLP-1 drugs, migraine drugs, and more.
Public comments will be accepted on proposed guideline updates until December 19, 2025.
Existing laws and guidelines that refer to CDC guidelines would shift to “nationally recognized clinical practice guidelines.”
Stakeholders provided feedback on the DWC’s proposed rules.
Interested stakeholders must submit written comments by October 28th.
